Cyclosporine A inhibits acetylcholinesterase activity in rats experimentally demyelinated with ethidium bromide

International Journal of Developmental Neuroscience

Volumn 25, Issue 4, 2007, Pages 259-264

  Mazzanti, Cinthia M ^a   Spanevello, Roselia ^a   Ahmed, Musthaq ^b   Schmatz, Roberta ^b   Mazzanti, Alexandre ^b   Salbego, Fabiano Z ^b   Graça, Dominguita L ^b   Sallis, Eliza S V ^b   Morsch, Vera M ^b   Schetinger, Maria Rosa C ^b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

Acetylcholinesterase; Cyclosporine A; Demyelination; Ethidium bromide; Rat

Indexed keywords

ACETYLCHOLINESTERASE; CYCLOSPORIN A; ETHIDIUM BROMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; DEMYELINATION; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; HIPPOCAMPUS; HYPOTHALAMUS; MALE; MULTIPLE SCLEROSIS; NONHUMAN; PONS; PRIORITY JOURNAL; RAT; WISTAR RAT;

ACETYLCHOLINESTERASE; ANALYSIS OF VARIANCE; ANIMALS; ANTIRHEUMATIC AGENTS; BRAIN; CYCLOSPORINE; DEMYELINATING DISEASES; DISEASE MODELS, ANIMAL; ETHIDIUM; MALE; RATS; RATS, WISTAR;

RATTUS;

EID: 34249318430     PISSN: 07365748     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijdevneu.2007.02.005     Document Type: Article

References (45)

1. Amato M.P., Portaccio E., and Zipoli V. Are there protective treatments for cognitive decline in MS?. J. Neurol. Sci. 245 (2006) 183-186
2. Appleyard M.E. Secreted acetylcholinesterase: non-classical aspects of a classical enzyme. TINS 15 (1992) 485-490
3. Blum D., Yonelinas A.P., Luks T., Newitt D., Oh J., Lu Y., Nelson S., Goodkin D., and Pelletier D. Dissociating perceptual and conceptual implicit memory in multiple sclerosis patients. Brain Cogn. 50 (2002) 51-61
4. Bjartmar C., Wujek B.D., and Trapp B.D. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J. Neurol. Sci. 206 (2003) 165-171
5. Bondan E.F., Lallo M.A., Sinhorini L.L., Pereira L.A.V., and Graça D.L. The effect of cyclophosphamide on brainstem remyelination following local ethidium bromide injection in Wistar rats. J. Submicrosc. Cytol. Pathol. 32 (2000) 603-612
6. Borlongan C.V., Stahl C.E., Keep M.F., Elmer E.E., and Watanabe S. Cyclosporine-A enhances choline acetylcholinesterase immunoreactivity in the septal region of adult rats. Neurosci. Lett. 279 (2000) 73-76
7. Bradford M.M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
8. Christodoulou C., Melville P., Scherl W.F., Mc Allister W.S., Elkins L.E., and Krupp L.B. Effects of donepezil on memory and cognition in multiple sclerosis. J. Neurol. Sci. 245 (2006) 127-136
9. Das A., Shanker G., Nath C., Pal R., Singh S., and Singh H.K. A comparative study in rodents of standardized extracts of Bacopa monniera and ginkgo biloba anticholinesterase and cognitive enhancing activities. Pharmacol. Biochem. Behav. 73 (2002) 893-900
10. DeSousa E.A., Albert R.H., and Kalman B. Cognitive impairments in multiple sclerosis: a review. Am. J. Alzheimer's Dis. Dementias 17 (2002) 23-29
11. D'Intimo G., Paradisi M., Fernandez M., Giuliani A., Aloe L., Giardino L., and Calza L. Cognitive deficit associated with cholinergic and nerve growth factor dow-regulation in experimental allergic encephalomyelitis in rats. PNAS 102 (2005) 3070-3075
12. Durak I., Ozbek H., and Elgun S. Cyclosporine reduces hepatic antioxidant capacity: protective roles of antioxidants. Int. Immunopharmacol. 4 (2004) 469-473
13. Ellmann G.L., Courtney K.D., Andres V., and Featherstone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7 (1961) 88-95
14. Faulds D., Goa K.L., and Benfield P. Cyclosporin: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in immunoregulatory disorders. Drugs 45 (1993) 953-1040
15. Freo U., Pizolato G., Dam M., Ori C., and Battistin L. A short review of cognitive and functional neuroimaging studies of cholinergic drugs: implications for therapeutic potentials. J. Neural Transm. 109 (2002) 857-870
16. Graça D.L., Bondan E.F., Pereira L.A.V.D., Fernandes C.G., and Maiorka C.P. Behaviour of oligodendrocytes and Schwann cells in an experimental model of toxic demyelination of the central nervous system. Arq. Neuropsiquiatr. 59 (2001) 358-361
17. Greene Y.M., Tariot P.N., Wishart H., Cox C., Holt C.J., Schwid S., and Noviask J. A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments. J. Clin. Psychopharm. 20 (2000) 350-356
18. Grisaru D., Sternfeld M., Eldor A., Glick D., and Soreq H. Structural roles of acetylcholinesterase variants in biology and pathology. Eur. J. Biochem. 264 (1999) 672-686
19. Guazzo E.P. A technique for producing demyelination of the rat optic nerves. J. Clin. Neurosci. 12 (2005) 54-58
20. Gustavson A.R., and Cummings J.L. Cholinesterase inhibitors in non-Alzheimer dementias. Am. Med. Directors Assoc. (2003) 165-169
21. Herink J., Krejcová G., and Bajgar J. Antiacetylcholinesterase activity of cyclosporine-a comparison of single and repeated administration and effect of 7-methoxytacrine. Acta Med. 45 (2002) 145-147
22. Herink J., Krejcová G., Bajgar J., Svoboda Z., Kvetina J., Zivnu P., and Palicka V. Cyclosporine A inhibits acetylcholinesterase activity in selected parts of the rat brain. Neurosci. Lett. 339 (2003) 251-253
23. Kappos L. Clinical trials of immunosuppression and immunomodulation in multiple sclerosis. J. Neuroimmunol. 20 (1988) 261-268
24. Kasa Sr. P., Papp H., Kasa Jr. P., Pakask I.M., and Balapiri L. Effects of amyloid-beta on cholinergic and acetylcholinesterase-positive cells in cultured basal forebrain neurons of embryonic rat brain. Brain Res. 998 (2004) 73-82
25. Kumar V., Anand R., Messina J., Hartman R., and Veach J. An efficacy and safety analysis of exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur. J. Neurol. 7 (2000) 159-169
26. Levine J.M., and Reynolds R. Activation and proliferation of endogenous oligodendrocyte precursor cells during ethidium bromide-induced demyelination. Exp. Neurol. 160 (1999) 333-347
27. Mazzanti C.M., Spanevello R.M., Pereira L.B., Gonçalves J.F., Kaizer R., Corrêa M., Ahmed M., Mazzanti A., Festugatto R., Graça D.L., Morsch V.M., and Schetinger M.R.C. Acetylcholinesterase activity in rats experimentally demyelinated with ethidium bromide and treated with interferon beta. Neurochem. Res. 31 (2006) 1027-1034
28. Mazzanti C.M., Spanevello R.M., Obregon A., Pereira L.B., Streher C.A., Ahmed M., Mazzanti A., Graça D.L., Morsch V.M., and Schetinger M.C. Ethidium bromide inhibits rat brain acetylcholinesterase activity in vitro. Chem. Biol. Interact. 162 (2006) 121-127
29. Masanic C.A., Baley M.T., VanRekum R., and Simard M. Open-label study of donepezil in traumatic brain injury. Arch. Phys. Med. Rehab. 82 (2001) 896-901
30. Mesulam M.M., Guillozet A., Shaw P., Levey A., Duysen E.G., and Lockridge O. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience 110 (2002) 627-639
31. Ohler B., Graf K., Bragg R., Lemons T., Coe R., Genain C., Israelachvil J., and Husted C. Role of lipid interactions in autoimmune demyelination. Biochim. Biophys. Acta 1688 (2004) 10-17
32. Parry A.M.M., Scott R.B., Palace J., Smith S., and Matthews P.M. Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine. Brain 126 (2003) 2750-2760
33. Porcel J., and Montalban X. Anticholinesterasics in the treatment of cognitive impairment in multiple sclerosis. J. Neurol. Sci. 245 (2006) 177-181
34. Potyk D. Treatment for Alzheimer disease. South. Med. J. 98 (2005) 628-635
35. Prado M.A.P., Reis R.A.M., Prado V.F., Mello M.C., Gómez M.V., and Mello F.G. Regulation of acetylcholine synthesis and storage. Neurochem. Int. 41 (2002) 291-299
36. Rees T., Hammond P.I., Soreq H., Younkin S., and Brimijoin S. Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex. Neurobiol. Aging 4 (2003) 777-787
37. Rocha J.B.T., Emanuelli T., and Pereira M.E. Effects of early undernutrition on kinetic parameters of brain acetylcholinesterase from adult rats. Acta Neurobiol. Exp. 53 (1993) 431-437
38. Rosecrantz R., Moon A., Raynes H., and Spivak W. Cyclosporine induced neurotoxicity during treatment of Crohn's disease: lack of correlation with previously reported risk factors. Am. J. Gastroent. 96 (2001) 2778-2782
39. Rosendal F., Bjarkam C.R., Larsen M., Hansen H.E., Madsen M., Sorensen J.C., and Mortensen J. Does chronic low-dose treatment with cyclosporine influence the brain ? A histopatological study in pigs. Transplant. Proc. 37 (2005) 3305-3308
40. Smith P.M., and Franklin R.J.M. The effect of immunosuppressive protocols on spontaneous CNS remyelination following toxin-induced demyelination. J. Neuroimmunol. 119 (2001) 261-268
41. Stangel M., and Hartung H.P. Remyelinating strategies for the treatment of multiple sclerosis. Prog. Neurobiol. 68 (2002) 361-376
42. Tõugu V., and Kesvatera T. Role of ionic interactions in cholinesterase catalysis. Biochim. Biophys. Acta 1298 (1996) 12-30
43. Weinstock M. The pharmacotherapy of Alzheimer's disease based on the cholinergic hypothesis: an update. Neurodegeneration 4 (1995) 349-356
44. Werber E.A., and Rabey J.M. The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia. J. Neural Trans. 108 (2001) 1319-1325
45. Yajima K., and Suzuki K. Demyelination and remyelination in the rat central nervous system following ethidium bromide injection. Lab. Invest. 41 (1979) 385-392